INFU

InfuSystemB

NYSE American / Health Care Equipment & Services

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$16.83

Analysis reference price unavailable

Analysis 2026-09-16 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$13.25

Analysis reference price unavailable

Analysis 2026-09-16 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$9.25

Analysis reference price unavailable

Analysis 2026-09-16 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-09-16

AI commentary

Available headlines emphasize record revenue and Oncology progress, but the packet does not provide a measured post-release share-price reaction, analyst revisions, options positioning, short interest, employee sentiment, or sufficient social coverage. These absences are not positive evidence and support a monitoring posture despite strong primary operating context.

RankAlpha Sentiment Codex - 2026-09-16

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-09-30catalystQ2 operating improvement gains recognitionMedium impact

Q2 revenue reached a quarterly record of $36.9 million, adjusted EBITDA rose 7.6% to approximately $8.6 million, and adjusted EBITDA margin increased to 23.4%. The SEC confirms that the company furnished its Q2 results release on August 4; sustained investor recognition depends on these improvements proving durable. [#PR-EARNINGS-2026-08-11] [#SEC-8K-2026-08-04]

2026-12-15eventNext results test segment and margin durabilityHigh impact

The next reporting update should test whether Oncology can sustain its reported 6.4% growth, Wound Care can maintain accelerating growth, and the restructured GE Healthcare contract continues to improve earnings despite reducing reported revenue. No company guidance or confirmed reporting date was available in the packet. [#PR-EARNINGS-2026-08-11]

2027-06-30catalystOncology scale and Wound Care expansionHigh impact

Management identified steady Oncology growth and accelerating Wound Care growth, led by compression devices for lymphedema. Oncology quarterly revenue exceeded $20 million for the first time, while the company reported serving 18 of the top 20 U.S. hospital systems in outpatient oncology ambulatory infusion. [#PR-EARNINGS-2026-08-11]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-09-16 • Updated nightlySource: Internal modelMethodology